News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Serologicals Corporation (SERO) Announces Collaboration With CXR Biosciences To Establish New Drug Screening Platform


10/19/2005 5:09:19 PM

ATLANTA--(BUSINESS WIRE)--June 22, 2005-- High Throughput In Vitro Multiple Readout Screens Expected to Reduce Development Time of New Therapies Serologicals Corporation (NASDAQ: SERO) today announced that Upstate Group, its wholly owned subsidiary, has initiated a collaboration with CXR Biosciences to establish a battery of proprietary in vitro screens to select, at an early stage, candidate molecules for further development. The underlying principle of the platform is to enable the identification of compounds with the most optimal safety or bioavailability profiles as early in the drug development process as possible. The result of this will be to advance molecules most likely to succeed into clinical development, thereby reducing the overall time-to-market of life-enhancing therapies. The screening platform will utilize predictive toxicity and drug metabolism screens to profile compounds in various cell-based and in vitro assays. Dr Tom Shepherd, Chief Executive of CXR commented "As a significant part of the tremendous costs involved in drug development are expended on drugs that fail during the development process, not only should this platform improve the quality of candidate drugs entering the clinic, but it should also improve the cost effectiveness of the overall process. Perhaps most importantly, this platform is intended to reduce the time-to-market of critical new life-enhancing therapies."

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES